目的: 探讨匹伐他汀联合血必净注射液对急性冠脉综合征( Acute coronary syndrome，ACS) 病人行
PCI 术后血清基质金属蛋白酶－9( MMP－9) 、五聚素3( PTX 3) 水平变化及生活质量的影响。方法: 选取2014－12
～ 2017－05 期间在我院接受PCI 治疗的112 例ACS 病人，按照随机数字表法分为观察组与对照组各56 例。两组
PCI 术后均行常规治疗，在此基础上，对照组术后给予匹伐他汀治疗，观察组给予匹伐他汀+血必净注射液治疗，
两组均连续治疗3mo。对比两组PCI 术前及术后3mo 血清( MMP－9、PTX 3) 水平、生活质量( QOL) 评分，统计两
组术后3mo 内不良心血管事件发生率及用药期间不良反应发生率。结果: ( 1) 血清MMP－9、PTX 3 水平: 两组血
清MMP－9、PTX 3 水平PCI 术前比较无显著差异( P 均＞0．05) ，PCI 术后3mo 两组血清MMP－9、PTX 3 水平均较
术前降低( P 均＜0．05) ，且观察组血清MMP－9、PTX 3 水平均低于对照组( P 均＜0．05) ; ( 2) 不良心血管事件发生
率: 观察组PCI 术后3mo 内不良心血管事件发生率3．57%( 2 /56) 较对照组14．29%( 8 /56) 低( P＜0．05) ; ( 3) 不良
反应: 观察组腹痛、倦怠感、皮肤痒感、药疹等不良反应发生率与对照组比较均无显著差异( P 均＞0．05) ; ( 4) 生活
质量: 两组QOL 评分PCI 术前比较无显著差异( P＞ 0．05) ，PCI 术后mo 两组QOL 评分均较术前提高( P 均＜
0．05) ，且观察组QOL 评分高于对照组( P＜0．05) 。结论: 匹伐他汀联合血必净注射液可有效改善ACS 病人PCI
术后血清MMP － 9、PTX 3 水平、降低不良心血管事件发生率，且具有一定安全性，有利于提高病人术后生活
质量

Objective: To investigate the effect of Atorvastatin combined with Xuebijing injection on
serum matrix metalloproteinase－9( MMP－9) and poly( five) 3( PTX 3) levels and quality of life in patients
with acute coronary syndrome( ACS) undergoing PCI．Methods: 112 patients with ACS who received
PCI treatment in our hospital from December 2014 to May 2017 were randomly divided into the
observation group and the control group with 56 cases in each group．Based on two groups of patients
treated with conventional treatment after PCI， the control group was given atorvastatin treatment，and the
observation group was given atorvastatin + Xuebijing injection treatment．The two groups were treated for
3months．The serum levels of PCI( MMP－9) ，PTX 3 and quality of life( QOL) were compared between
the two groups before and 3months after PCI operation．The incidence of adverse cardiovascular events
and the incidence of adverse drug reactions during the 3months after operation in the two groups were
counted．Ｒesults: ( 1) Serum MMP － 9 and PTX 3 levels: there was insignificant difference in serum
levels of MMP－9 and PTX 3 between the two groups before PCI( P＞0．05) ．3months after PCI， the levels
of serum MMP－9 and PTX 3 in two groups were lower than those before operation( P＜0．05) ．And
the serum levels of MMP－9 and PTX 3 in the observation group were lower than those in the control
group( P＜0．05) ．( 2) The incidence of adverse cardiovascular events: the incidence of adverse cardiovascular
events within 3months after PCI in the observation group was 3．57%( 2 /56) ，which was lower
than that of the control group 14．29%( 8 /56) ( P＜0．05) ．( 3) Adverse reactions: there was insignificant
difference in the incidence of adverse reactions such as abdominal pain， lassitude， skin itching and drug
eruption between the observation group and the control group( P＞0．05) ．( 4) Quality of life: there was
insignificant difference in QOL score between the two groups before PCI( P＞0．05) ，and the QOL scores
of the two groups after 3months of PCI were higher than those before the operation( P＜0．05) ，and the
QOL score of the observation group was higher than that of the control group( P＜0．05) ．Conclusion:
Atorvastatin combined with Xuebijing injection can effectively improve the ACS after PCI in patients
with serum MMP－9 and PTX 3 levels， reduce the incidence of adverse cardiovascular events，and it has
a certain safety．It’s conducive to improve the quality of life of patients after operation．

Ｒ54

 收稿日期: 2017－10－22; 修回日期: 2018－01－19
基金项目: 内蒙古卫生厅基金( 201303042)
作者简介: 张玉蓉( 1975－) ，女，湖北民族学院附属民大医院主治医师。
通讯作者: 张晓云，教授，E－mail: xiaoyun－223@ 163．com 内蒙古医科大学附属医院保健病房B 区， 010050